Adicet Bio, Inc. Increase (Decrease) in Accounts Receivable, Related Parties
Adicet Bio, Inc. (ACET) reported Increase (Decrease) in Accounts Receivable, Related Parties of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties · last filed 2023-11-08
- Adicet Bio, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Adicet Bio, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2023-06-30 was $0.00.
- Adicet Bio, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2023-03-31 was $0.00.
- Adicet Bio, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2022-12-31 was -$29.00K, a 196.67% decline year-over-year.
- Adicet Bio, Inc. increase (decrease) in accounts receivable, related parties for fiscal 2022 was -$185.00K, a 716.67% decline from fiscal 2021.
- Adicet Bio, Inc. increase (decrease) in accounts receivable, related parties for fiscal 2021 was $30.00K.
| Period end | Increase (Decrease) in Accounts Receivable, Related Parties 3 month | Increase (Decrease) in Accounts Receivable, Related Parties 6 month | Increase (Decrease) in Accounts Receivable, Related Parties 9 month | Increase (Decrease) in Accounts Receivable, Related Parties 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | -$29.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | -$29.00K derived: sum of 3 quarters · filed 2023-08-09 | $0.00 derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | -$29.00K derived: sum of 2 quarters · filed 2023-05-09 | $0.00 derived: sum of 3 quarters · filed 2023-11-08 | $0.00 derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-12-31 | -$29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 derived: sum of 3 quarters · filed 2023-11-08 | -$185.00K 10-K · filed 2023-03-15 |
| 2022-09-30 | $29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $29.00K derived: sum of 2 quarters · filed 2023-11-08 | -$156.00K 10-Q · filed 2023-11-08 | -$126.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$185.00K 10-Q · filed 2023-08-09 | -$155.00K derived: sum of 3 quarters · filed 2023-08-09 | -$155.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$185.00K 10-Q · filed 2023-05-09 | -$155.00K derived: sum of 2 quarters · filed 2023-05-09 | -$155.00K derived: sum of 3 quarters · filed 2023-05-09 | |
| 2021-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $30.00K derived: sum of 2 quarters · filed 2023-03-15 | $30.00K 10-K · filed 2023-03-15 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |